Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
NCT ID NCT07677852
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study investigates sexual and urinary problems in people with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. While visible symptoms like droopy eyelids are well-known, issues like sexual dysfunction and bladder problems are often ignored. Researchers will use questionnaires to measure how common these hidden symptoms are and how they affect quality of life. The goal is to help doctors better recognize and address these underreported concerns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors recognize and address hidden symptoms like sexual and bladder issues in myasthenia gravis, potentially improving patients' quality of life.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly change how the disease is managed. The results may not apply to all patients with myasthenia gravis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP and Myology institute
Paris, 75000, France
-
Nice University hospital
Nice, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Engineered immune cells take aim at autoimmune diseases
- New drug aims to ease daily struggles of myasthenia gravis
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
- New study aims to uncover hidden clues in myasthenia gravis
- CAR t therapy takes on lupus, MS, and more in first human safety trial